OliX Pharmaceuticals ... The stock price surged following the news that it signed a license agreement with Eli Lilly on cardiovascular and metabolic disease treatments on the 7th.

This is Lilly’s second MASH deal this year, following its partnership with OliX Pharmaceuticals on the RNAi drug OLX75016. The OliX deal also included a drug with data supporting its use with a ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

The company entered into a global licensing deal with South Korea's OliX Pharmaceuticals that could be valued at up to $630 million. As per the agreement, Eli Lilly and Company (NYSE:LLY ...

According to this contract, OliX must complete Phase 1 clinical trials for OLX75016. Following that, clinical development and commercialization will be handled by Eli Lilly and Company (NYSE ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, ...